Seroatlas · Human Serome Atlas

ZPBP2

Zona pellucida-binding protein 2

Also known as: MGC41930, ZPBP2_HUMAN, ZPBPL

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6X784
Gene: ZPBP2
Ensembl: ENSG00000186075
Chromosome: 17
Canonical length: 338 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted in male reproductive system

OverviewNCBI Gene

Predicted to be involved in acrosome assembly and binding activity of sperm to zona pellucida. Predicted to act upstream of or within membrane lipid metabolic process and regulation of gene expression. Located in nucleus. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

338 residues, UniProt reviewed canonical sequence.

>Q6X784|ZPBP2
     1  MMRTCVLLSA VLWCLTGVQC PRFTLFNKKG FIYGKTGQPD KIYVELHQNS PVLICMDFKL
    61  SKKEIVDPTY LWIGPNEKTL TGNNRINITE TGQLMVKDFL EPLSGLYTCT LSYKTVKAET
   121  QEEKTVKKRY DFMVFAYREP DYSYQMAVRF TTRSCIGRYN DVFFRVLKKI LDSLISDLSC
   181  HVIEPSYKCH SVEIPEHGLI HELFIAFQVN PFAPGWKGAC NGSVDCEDTT NHNILQARDR
   241  IEDFFRSQAY IFYHNFNKTL PAMHFVDHSL QVVRLDSCRP GFGKNERLHS NCASCCVVCS
   301  PATFSPDVNV TCQTCVSVLT YGAKSCPQTS NKNQQYED

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ZPBP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.34
Highest tissue expression: 89 nTPM

Expression across tissuesHPA

Tissue

testis: 89 nTPM
tonsil: 0.8 nTPM
lymph node: 0.6 nTPM
retina: 0.5 nTPM
appendix: 0.3 nTPM
bone marrow: 0.3 nTPM

Single-cell type

late primary spermatocytes: 882 nCPM
early primary spermatocytes: 242 nCPM
early spermatids: 207 nCPM
late spermatids: 107 nCPM
undifferentiated spermatogonia: 5.4 nCPM
epididymal basal cells: 4.6 nCPM

Immune cell

naive B-cell: 0.4 nTPM
memory B-cell: 0.1 nTPM
memory CD8 T-cell: 0.1 nTPM
naive CD4 T-cell: 0.1 nTPM
naive CD8 T-cell: 0.1 nTPM
basophil: 0 nTPM

Brain region

white matter: 4.9 nTPM
cerebellum: 4.8 nTPM
cerebral cortex: 4.7 nTPM
hypothalamus: 4.3 nTPM
basal ganglia: 4.1 nTPM
amygdala: 4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.26
gnomAD pLI: 0
gnomAD missense Z: 0.42
DepMap mean gene effect: -0.15
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ZPBP2 as an antibody target. Whether an autoantibody or antibody against ZPBP2 could matter depends on whether native ZPBP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ZPBP2 is annotated as secreted, so native ZPBP2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label ZPBP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...